Equity Overview
Price & Market Data
Price: $1.09
Daily Change: -$0.07 / 6.42%
Range: $1.09 - $1.19
Market Cap: $58,422,632
Volume: 620,341
Performance Metrics
1 Week: 33.41%
1 Month: -42.02%
3 Months: -46.83%
6 Months: -25.85%
1 Year: -33.13%
YTD: -53.81%
Company Details
Employees: 33
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Canada
Details
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.